Deutsche Bank set a $30.00 price target on Bausch Health Companies (NYSE:BHC) in a research report sent to investors on Wednesday. The firm currently has a buy rating on the stock.

BHC has been the subject of several other reports. ValuEngine downgraded shares of Bausch Health Companies from a hold rating to a sell rating in a research note on Friday, September 7th. Piper Jaffray Companies set a $16.00 target price on shares of Bausch Health Companies and gave the company a sell rating in a research note on Tuesday, August 7th. Wells Fargo & Co restated a sell rating on shares of Bausch Health Companies in a research note on Monday, August 6th. Cantor Fitzgerald restated a buy rating and issued a $32.00 target price on shares of Bausch Health Companies in a research note on Wednesday. Finally, Mizuho restated a buy rating and issued a $31.00 target price on shares of Bausch Health Companies in a research note on Tuesday, August 7th. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the stock. Bausch Health Companies has an average rating of Hold and an average target price of $25.38.

Shares of BHC opened at $22.35 on Wednesday. The company has a market capitalization of $8.21 billion, a price-to-earnings ratio of 6.13, a PEG ratio of 0.34 and a beta of -0.43. Bausch Health Companies has a twelve month low of $10.94 and a twelve month high of $27.79. The company has a debt-to-equity ratio of 6.99, a current ratio of 1.14 and a quick ratio of 0.89.

Bausch Health Companies (NYSE:BHC) last announced its earnings results on Tuesday, August 7th. The company reported $0.93 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.81 by $0.12. The company had revenue of $2.13 billion during the quarter, compared to the consensus estimate of $2.05 billion. Bausch Health Companies had a negative net margin of 20.60% and a positive return on equity of 27.83%. equities analysts predict that Bausch Health Companies will post 3.47 earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of the company. Marshall Wace LLP acquired a new stake in shares of Bausch Health Companies during the second quarter worth $2,974,000. Van ECK Associates Corp acquired a new stake in shares of Bausch Health Companies during the second quarter worth $11,494,000. Private Management Group Inc. acquired a new stake in shares of Bausch Health Companies during the second quarter worth $28,474,000. Point View Wealth Management Inc. acquired a new stake in shares of Bausch Health Companies during the second quarter worth $1,132,000. Finally, Tobam acquired a new stake in shares of Bausch Health Companies during the second quarter worth $13,886,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

Bausch Health Companies Company Profile

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. It offers dermatology products that treat a range of conditions, including actinic keratosis, acne, atopic dermatitis, psoriasis, cold sores, athlete's foot, nail fungus, and other dermatoses, as well as provides aesthetic medical devices, which address various conditions, including facial wrinkles, acne, pigmentation conditions, body sculpting, skin tightening, and laser hair removal.

Featured Article: How Do I Invest in Dividend Stocks

Analyst Recommendations for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.